We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| HUTCHMED China Limited | AQSE:HCM.GB | Aquis Stock Exchange | Ordinary Share | KYG4672N1198 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| -10.00 | -3.23% | 300.00 | 290.00 | 310.00 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 310.00 | 300.00 | 310.00 | 350 | 11:00:54 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 11/1/2024 | 07:00 | RNSNON | Hutchmed (China) Limited Sovleplenib NDA Granted Priority Review in China |
| 29/12/2023 | 08:30 | UKREG | Hutchmed (China) Limited Total Voting Rights |
| 29/12/2023 | 08:30 | UKREG | Hutchmed (China) Limited Blocklisting Six Monthly Return |
| 21/12/2023 | 10:00 | UKREG | Hutchmed (China) Limited Overseas Regulatory Announcement |
| 13/12/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Inclusion in National Reimbursement Drug List |
| 07/12/2023 | 10:04 | UKREG | Hutchmed (China) Limited Overseas Regulatory Announcement |
| 01/12/2023 | 07:00 | RNSNON | Hutchmed (China) Limited Clinical Data to be Presented at Congresses |
| 30/11/2023 | 08:30 | UKREG | Hutchmed (China) Limited Total Voting Rights |
| 09/11/2023 | 07:00 | UKREG | Hutchmed (China) Limited U.S. FDA Approval of FRUZAQLA(TM) (fruquintinib) |
| 24/10/2023 | 09:30 | UKREG | Hutchmed (China) Limited Vesting of awards under the LTIP |
1 Year HUTCHMED China Chart |
Intraday HUTCHMED China Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
